View abstract

This abstract is assigned to sessions

Title

Ozurdex implant migration into the Anterior chamber

Purpose	Ozurdex (Allergan Inc, Irvine, CA, USA) is a biodegradable sustained release device containing 0.7 mg of dexamethasone in a solid polymer drug delivery system. It is approved for the management of macular oedema associated with central and branch retinal vein occlusion, diabetic macular oedema and non-infectious uveitis. With increasing use of this non-tethered steroid implant we continue to learn about potential risks associated with the treatment and thus learn about considerations prior to starting such a treatment and also how to manage such complications should they arise.
Methods	Here we present a case of a 61 year old male who unfortunately developed one of the rarer complications of an Ozurdex implant. 11 days following the implant, the patient noticed the implant in the anterior chamber of his eye leading to corneal endothelium decompensation, and thus the deterioration in his vision
Results	the patient continued to have corneal oedema due to endothelial cell loss
Conclusion	We review the risk factors of Ozurdex implant migration, and how to manage the patients that develop such a complication
Conflict of interest	No

Authors 1

Last name	NARDEOSINGH
Initials	S
Department	Ophthalmology
City	Glasgow

Authors 2

Last name	Elhassan
Initials	S
Department	Ophthalmology
City	Cardiff

Authors 3

Last name	Williams
Initials	G
Department	Ophthalmology
City	Swansea

Authors 4

Last name	Hill
Initials	R
Department	Ophthalmology
City	Swansea